Zai Lab Says First Patient Treated In Mainland China For Global Phase 3 FORTITUDE-101 Study Of Bemarituzumab In First-Line Gastric Cancer
Portfolio Pulse from Benzinga Newsdesk
Zai Lab has announced the treatment of the first patient in Mainland China as part of its global Phase 3 FORTITUDE-101 study of Bemarituzumab in first-line gastric cancer.
July 14, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zai Lab's initiation of patient treatment in China for its global Phase 3 FORTITUDE-101 study could potentially boost its stock as it indicates progress in its research.
The initiation of patient treatment in a new region, especially a large market like China, is a positive development for Zai Lab. This could potentially attract more investors, driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100